Sign in

You're signed outSign in or to get full access.

BI

Bioventus Inc. (BVS)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 delivered resilient execution: revenue $147.7M (-2.4% reported; +6.2% organic), GAAP diluted EPS $0.11 (vs. prior-year -$0.40), and Non-GAAP EPS $0.21 (+31% YoY); adjusted EBITDA was $33.8M with ~23% margin, supported by gross margin mix and disciplined OpEx .
  • Against S&P Global consensus, Bioventus posted a modest beat: revenue $147.7M vs. $145.9M*, EPS $0.21 vs. $0.197*, and EBITDA (company non-GAAP) $33.8M vs. $29.9M*; management reaffirmed full-year guidance (net sales $560–$570M, adj. EBITDA $112–$116M, Non-GAAP EPS $0.64–$0.68) . Values retrieved from S&P Global.
  • Surgical Solutions grew 11.4% YoY, Restorative Therapies grew 11.2% organically (despite divestiture headwind), while Pain Treatments rose 1.5% led by DUROLANE volume; international revenue increased 12.4% (+24.0% organic) .
  • Strategic catalysts: FDA 510(k) clearances for TalisMann and StimTrial (PNS) with limited launch in Q3 and broader rollout in early 2026, plus a new $400M credit agreement reducing interest margins by 75 bps and extending maturities to 2030 .
  • Near-term stock reaction drivers: confirmation of non-opioid PNS launch timing and adoption, sustained Ultrasonics capital placements, and reiterated annual guidance despite FX/tariff headwinds (~$5M combined headwinds absorbed year-to-date) .

What Went Well and What Went Wrong

What Went Well

  • Double-digit growth in Ultrasonics and accelerating Bone Graft Substitutes (BGS) in Surgical Solutions; “we delivered strong double digit growth in ultrasonics…enhanced precision…reduced patient blood loss, and increased OR efficiency” .
  • EXOGEN drove double-digit organic growth in Restorative Therapies; management highlighted “improvement in commercial effectiveness and sales force execution” and momentum to return the category above $100M over time .
  • Cash generation accelerated: cash from operations $25.9M (+$10.8M YoY), with management targeting net leverage below 2.5x by 2025 and interest savings >$2M annually from the new credit agreement .

What Went Wrong

  • FX and tariffs: year-to-date FX headwind >$2M and updated tariff impact ~$3M for 2025; adjusted EBITDA dipped vs. prior year due to divestiture and FX .
  • Pain Treatments price pressure and tough comps temporarily slowed growth; management cited lower ASPs and a challenging comparison to prior year despite DUROLANE volume strength .
  • Reported revenue decline (-2.4%) reflects the Advanced Rehabilitation divestiture; Restorative Therapies reported -31.6% YoY with only $0.2M of divested revenue remaining in the quarter .

Financial Results

Consolidated Performance vs. Prior Periods

MetricQ2 2024Q1 2025Q2 2025
Revenue ($USD Millions)$151.217 $123.876 $147.660
GAAP Diluted EPS ($)-$0.40 -$0.04 $0.11
Non-GAAP EPS ($)$0.16 $0.08 $0.21
Gross Margin % (GAAP)68.5% 67.0% 69.1%
Gross Margin % (Non-GAAP)75.8% 75.3% 76.3%
Operating Income (GAAP, $M)-$31.473 $4.869 $18.368
Non-GAAP Operating Income ($M)$28.834 $17.699 $30.645
Non-GAAP Operating Margin %19.1% 14.3% 20.8%
Adjusted EBITDA ($M)$34.452 $19.212 $33.751
Cash from Operations ($M)$15.162 -$19.331 $25.938

Actual vs. S&P Global Consensus (Q2 2025)

MetricConsensus*Actual
Revenue ($USD Millions)$145.863*$147.660
Primary EPS ($)$0.1967*$0.21
EBITDA ($USD Millions)$29.853*$33.751
Values retrieved from S&P Global.

Segment Breakdown (Q2 2025 vs. Q2 2024)

SegmentQ2 2024 ($000s)Q2 2025 ($000s)Change ($000s)Change (%)
Pain Treatments$72,260 $73,308 $1,048 1.5%
Surgical Solutions$47,337 $52,716 $5,379 11.4%
Restorative Therapies$31,620 $21,636 -$9,984 -31.6%
Total Net Sales$151,217 $147,660 -$3,557 -2.4%

Geographic Mix (Q2 2025 vs. Q2 2024)

GeographyQ2 2024 ($000s)Q2 2025 ($000s)Change ($000s)Change (%)
U.S. Total$134,409 $128,775 -$5,634 -4.2%
International Total$16,808 $18,885 $2,077 12.4%

KPIs and Balance Sheet Snapshot

KPIQ2 2024Q1 2025Q2 2025
Cash & Equivalents ($M)$31.994 $22.802 $32.910
Outstanding Debt ($M)——$341 (incl. $5 revolver)
Diluted Shares (Class A)64,056,759 66,008,683 68,536,759

Guidance Changes

MetricPeriodPrevious Guidance (May 6, 2025)Current Guidance (Aug 6, 2025)Change
Net Sales ($M)FY 2025$560–$570 $560–$570 Maintained
Adjusted EBITDA ($M)FY 2025$112–$116 $112–$116 Maintained
Non-GAAP EPS ($)FY 2025$0.64–$0.68 $0.64–$0.68 Maintained
Tariff Impact Assumption ($M)FY 2025“immaterial at this time” ~$3 (within ~$5 FX+tariff absorbed) Updated (clarified)
FX AssumptionH2 2025—No additional USD fluctuation assumed Clarified

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2: Q4 2024)Previous Mentions (Q-1: Q1 2025)Current Period (Q2 2025)Trend
Surgical Solutions (Ultrasonics/BGS)Double-digit growth sustained; capital placements strong Double-digit Ultrasonics; BGS ramp expected with new distributors Ultrasonics strong; BGS high-single-digit and accelerating into H2 Improving momentum
Pain Treatments (DUROLANE, pricing)Double-digit growth Q4; strong U.S. demand Double-digit DUROLANE volume; distributor buy timing impacted growth 1.5% growth; DUROLANE volume up, pricing/comps weighed; IDN account focus Near-term normalization, H2 acceleration
Restorative Therapies (EXOGEN)Stable; divestiture completed Organic +4%; commercial effectiveness improving Organic +11.2%; double-digit growth; reclaiming lost/existing/new customers Strengthening
PNS/PRP pipeline (TalisMann/StimTrial)—PRP distribution agreement with APEX Biologix Two FDA clearances (PNS), limited Q3 launch; broader rollout early 2026 New growth vector
FX/Tariffs—Initial tariffs “immaterial”; FX noted ~$3M tariffs expected for 2025; >$2M FX headwind absorbed YTD Headwinds managed
Capital structure/liquidityReduced debt Q4; cash from ops improved Revolver activity; CFO improved New $400M credit agreement; -75 bps margin; maturity to 2030 Flexibility improved

Management Commentary

  • CEO framing: “we are well positioned to accelerate revenue growth, profitability and cash flow… above market organic growth of 6%… adjusted EBITDA margin of 23%” .
  • PNS strategy: “StimTrial… allows physicians to evaluate a patient’s response… complemented by our new TalisMann PNS system… to potentially reach deeper, larger nerves” with limited 2H25 launch and broader rollout in early 2026 .
  • Portfolio ambition: “we will continue marching toward becoming a $1 billion high growth, high margin, high cash flow company” .
  • CFO on cash/leverage: “cash from operations totaled $26M… expect net leverage to fall to below 2.5x by [end of] 2025” .
  • Guidance posture: reaffirmed 2025 guidance, absorbing ~$5M combined FX/tariff headwinds; no additional USD fluctuation assumed in H2 .

Q&A Highlights

  • Pain Treatments trajectory: normalized organic growth would have been ~4–5% vs. reported 1%; DUROLANE volume slightly above mid-single-digit market growth; H2 acceleration supported by new IDN and account wins .
  • Surgical Solutions/BGS: BGS growth moved from low-single digits in Q1 to high-single digits in Q2; Ultrasonics capital placements strong, seen as leading indicator for sustained growth into 2026 .
  • Restorative Therapies (EXOGEN): double-digit growth driven by commercial execution; confidence in sustaining mid-single-digit or above growth longer-term .
  • OpEx outlook: slight increase in H2 with commissions tied to BGS ramp and investments in PNS/PRP; continued discipline to deliver EBITDA with revenue growth .
  • Tariffs/FX: 2025 tariffs ~$3M concentrated in H2; FX headwind >$2M absorbed YTD; guidance maintained despite these headwinds .

Estimates Context

  • Q2 2025 actuals vs. S&P Global consensus: revenue $147.7M vs. $145.9M*, Primary EPS $0.21 vs. $0.197*, EBITDA $33.8M (company non-GAAP) vs. $29.9M*; all modest beats. Values retrieved from S&P Global.
  • Forward periods: Q3 2025 consensus shows Primary EPS $0.115* and revenue $138.19M*, providing a conservative base; management reiterated full-year guidance and expects H2 acceleration across Pain, BGS, and Ultrasonics . Values retrieved from S&P Global.
  • Note: Definitions differ (Adjusted vs. GAAP EBITDA); SPGI “EBITDA Consensus” may not equal company’s “Adjusted EBITDA,” so compare directionally rather than one-for-one.

Key Takeaways for Investors

  • Evidence of resilient execution: organic +6.2%, Non-GAAP EPS $0.21, adjusted EBITDA ~$33.8M with 76.3% Non-GAAP gross margin—positioned for H2 acceleration across core businesses .
  • Surgical Solutions remains a structural growth driver (Ultrasonics strength, BGS acceleration), underpinning margin mix benefits and capital placement-led runway .
  • Pain Treatments to re-accelerate in H2 as comps normalize and IDN strategy gains traction; pricing pressure manageable given DUROLANE differentiation and payer coverage .
  • New PNS platform (TalisMann/StimTrial) creates a multi-year growth vector with limited launch in Q3 and broader rollout early 2026; watch adoption curves and reimbursement dynamics .
  • Liquidity/cost of capital improved: new $400M facility (-75 bps margin, 2030 maturity) supports deleveraging and optionality; >$2M annual interest savings is accretive to EPS/FCF .
  • Guidance reaffirmed despite FX/tariff headwinds; monitor macro FX/USD move and tariff updates—management assumes no incremental USD impact in H2 .
  • Near-term trade: bias to upside on confirmation of H2 growth inflection (Pain/BGS), Ultrasonics capital placements, and early PNS launch feedback; mid-term thesis leverages portfolio shift to higher growth/margin platforms .